"Executive Summary Chronic Granulomatous Disease Treatment Market Research: Share and Size Intelligence The Global Chronic Granulomatous Disease Treatment Market size was valued at USD 1.27 billion in 2024 and is expected to reach USD 1.77 billion by 2032, at a CAGR of 4.20% during the forecast period Best-practice models and research methodologies have been...

The global Methylmalonic Acidemia (MMA) market was valued at USD 9.16 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.0% during the forecast period. This growth is driven by increased awareness of rare metabolic disorders, the introduction of advanced diagnostic tools, and the rising investment in orphan drug development. Methylmalonic...